Company news

GSK plc news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Proxy Form 2026

March 25, 2026

Notice of AGM 2026

March 25, 2026

Admission to Trading

March 23, 2026

GSK Lung Cancer ADC Gets Japan Orphan Drug Status

March 23, 2026

Lynavoy (linerixibat) approved by US FDA

March 19, 2026

US FDA approves Arexvy for adults 18-49 AIR

March 13, 2026

Board Committee Change

March 9, 2026

GSK and Alfasigma agree global linerixibat rights

March 9, 2026

Filing of GSK plc 2025 Annual Report on Form 20-F

March 6, 2026

GSK publishes Annual Report 2025

March 5, 2026

GSK completes acquisition of RAPT Therapeutics

March 3, 2026

Total Voting Rights

March 2, 2026

Linerixibat accepted for priority review in China

February 26, 2026

Bepirovirsen accepted for Japan regulatory review

February 26, 2026

GSK enters agreement to acquire 35Pharma

February 25, 2026

Bora Pharmaceuticals and GSK Sign $250M Five Year Global Manufacturing Contract

February 23, 2026

GSK’s AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study Shows

February 18, 2026

GSK - fourth tranche of share buyback programme

February 17, 2026

Exdensur approved by the European Commission

February 17, 2026

China CDE accepts Arexvy adults 60+ application

February 10, 2026

Director/PDMR Shareholding

February 9, 2026

Nucala COPD approved by the European Commission

February 6, 2026

Final Results

February 4, 2026

European Commission approves Arexvy for adults 18+

January 26, 2026

GSK Awards $2M in COiMMUNITY Initiative Grants to Help Close Vaccination Gaps, Commits $3M for 2026

January 21, 2026

GSK Announces Recipients of Linked by Lupus: Optimal Care Initiative Grants Nearing $1 Million

January 20, 2026

GSK to acquire RAPT Therapeutics

January 20, 2026

Agreement on changes to ViiV minority shareholding

January 20, 2026

EC approval of Shingrix PFS

January 7, 2026

Positive phase 3 data for GSK's bepirovirsen

January 7, 2026

Exdensur approved in Japan

January 6, 2026

Nucala for adults with COPD approved in China

January 5, 2026

Transaction in Own Shares

December 22, 2025

GSK to lower drug prices and expand access in US

December 22, 2025

Exdensur (depemokimab ulla) approved by US FDA

December 17, 2025

Exdensur (depemokimab) UK MHRA approval

December 16, 2025

Nucala receives positive CHMP opinion for COPD

December 12, 2025

Depemokimab receives positive CHMP opinion

December 12, 2025

Positive CHMP opinion on Arexvy for all adults 18+

December 12, 2025

Blujepa approved in US for gonorrhoea indication

December 11, 2025

Block Listing Application

December 11, 2025

GSK'227 US FDA Orphan Drug Designation in SCLC

December 10, 2025

Initiation of litigation against AnaptysBio Inc

November 21, 2025

Transfer of Treasury Shares

November 19, 2025

Block listing Interim Review

November 12, 2025

GSK publishes provisional dividend dates

November 10, 2025

3rd Quarter Results

October 29, 2025

GSK ADC gets orphan drug designation in the EU

October 28, 2025

Blenrep approved by US FDA in multiple myeloma

October 24, 2025

Blenrep approved by US FDA for use in treatment of relapsed/refractory multiple myeloma

October 23, 2025

← Newer news releases · Older news releases →

Calls

The 5 newest of 27 calls. Every call is listed under its year.

Decks

The 5 newest of 181 decks. Every deck is listed under its year.